Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer

BACKGROUND: Programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy fails in the majority of patients with cancer. Oncolytic viruses represent a new class of therapeutic agents, yet the therapeutic efficacy is still disappointing. Moreover, intratumoral injection of viruses...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Fan, Guo, Zong Sheng, Gregory, Alyssa D, Shapiro, Steven D, Xiao, Gutian, Qu, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254155/
https://www.ncbi.nlm.nih.gov/pubmed/32461344
http://dx.doi.org/10.1136/jitc-2019-000294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254155/
https://www.ncbi.nlm.nih.gov/pubmed/32461344
http://dx.doi.org/10.1136/jitc-2019-000294

Ejemplares similares